Science & Technology
Fri, November 7, 2025
Thu, November 6, 2025
Wed, November 5, 2025
Janus Henderson Global Life Sciences Fund Q3 2025 Portfolio Update
//science-technology.news-articles.net/content/2 .. life-sciences-fund-q3-2025-portfolio-update.html
Published in Science and Technology on Thursday, November 6th 2025 at 0:50 GMT by Seeking Alpha- 🞛 This publication is a summary or evaluation of another publication
- 🞛 This publication contains editorial commentary or bias from the source
Sarepta Therapeutics (SRPT) – added for its AAV‑based gene therapy for Duchenne muscular dystrophy. Kiadis Pharma (KPTX) – brought in for its oncology cell‑therapy program targeting triple‑negative breast cancer. Exact Sciences (EXAS) – a diagnostic leader in colorectal cancer screening.
Conversely, the fund reduced exposure to Biogen (BIIB) by 2.1 percentage points, citing a slowdown in its mRNA vaccine pipeline and shifting emphasis toward newer, high‑growth biotech ventures.
Investment Thesis and Outlook
Janus Henderson’s manager emphasizes a forward‑looking investment thesis that hinges on the convergence of precision medicine, gene editing, and digital health. The firm believes that the integration of AI and genomics will accelerate drug discovery, reduce time‑to‑market, and lower development costs. The update cites the fund’s “dynamic allocation model” that allows rapid positioning in breakthrough technologies while maintaining a disciplined risk framework.
The fund’s risk management strategy remains anchored by a diversified geographic footprint. While 74.6 % of the portfolio is concentrated in North America and Europe, the fund still holds 11.2 % in emerging markets such as China and India, primarily in local biopharma and diagnostic companies.
Liquidity and Expense
Liquidity remains high, with a 3‑month turnover rate of 18.5 %. The fund’s expense ratio of 0.79 % aligns with its peers in the actively managed life‑sciences segment. Management notes that the lower expense ratio relative to index‑tracking funds translates into better risk‑adjusted returns.
Key Takeaways
- Strong Q3 performance – 12.4 % net return, outperforming the MSCI World Life Sciences Index.
- Increased biotech exposure – 62.8 % of the portfolio now in biotech, up 4.1 percentage points YoY.
- High‑growth focus – New positions in gene therapy (CRISPR Therapeutics, Sarepta), diagnostics (Exact Sciences), and cell therapy (Kiadis Pharma).
- Strategic divestment – Reduced stake in Biogen to free capital for higher‑potential opportunities.
- Forward‑looking thesis – Emphasis on precision medicine, AI integration, and digital diagnostics.
For investors and analysts interested in the full portfolio breakdown, Janus Henderson provides a downloadable PDF of the latest holdings list, which can be accessed from the firm’s official website (https://www.janushenderson.com/). The firm also offers a quarterly research note detailing the macro‑economic and regulatory environment impacting the life‑sciences sector.
Read the Full Seeking Alpha Article at:
[ https://seekingalpha.com/article/4838873-janus-henderson-global-life-sciences-fund-q3-2025-portfolio-update ]